Modification of commercial liposomal drug carrier by plasmon resonant coating

S. S. Knights-Mitchell, Marek Romanowski

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Multiple liposomal drugs have been successfully marketed as pharmaceuticals within the past two decades. Some of these clinically approved drugs, Doxil® in particular, have been shown to selectively localize within tumors due to the enhanced permeability and retention effect. However, a limitation exists with the inability to control content release once the drug gets to the desired location. Here we investigated the ability to apply a plasmon resonant coating to commercially available Doxil with the intention of spatially and temporally controlling doxorubicin release. While Doxil was successfully gold coated with a maximum plasmon resonant peak at 631 nm, the release at elevated temperature and on exposure to light was less than 10%. This result is similar to that observed for uncoated Doxil. Decreasing the pH had the same effect on both uncoated and plasmon resonant sample where a 10% increase in release was observed after samples were exposed to elevated temperature. Development of a highly efficient mechanism of light-activated drug release from Doxil will require a temperature-sensitive lipid composition.

Original languageEnglish (US)
Title of host publicationTechnical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014
PublisherNano Science and Technology Institute
Pages311-314
Number of pages4
Volume2
ISBN (Print)9781482258271
StatePublished - 2014
EventNanotechnology 2014: MEMS, Fluidics, Bio Systems, Medical, Computational and Photonics - 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014 - Washington, DC, United States
Duration: Jun 15 2014Jun 18 2014

Other

OtherNanotechnology 2014: MEMS, Fluidics, Bio Systems, Medical, Computational and Photonics - 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014
CountryUnited States
CityWashington, DC
Period6/15/146/18/14

Fingerprint

Drug Carriers
Coatings
Pharmaceutical Preparations
Drug products
Temperature
Lipids
Tumors
Gold
Doxorubicin
Chemical analysis
liposomal doxorubicin

Keywords

  • Controlled release
  • Doxil
  • Doxorubicin
  • Liposomes
  • Plasmon resonance

ASJC Scopus subject areas

  • Hardware and Architecture
  • Electrical and Electronic Engineering
  • Electronic, Optical and Magnetic Materials

Cite this

Knights-Mitchell, S. S., & Romanowski, M. (2014). Modification of commercial liposomal drug carrier by plasmon resonant coating. In Technical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014 (Vol. 2, pp. 311-314). Nano Science and Technology Institute.

Modification of commercial liposomal drug carrier by plasmon resonant coating. / Knights-Mitchell, S. S.; Romanowski, Marek.

Technical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014. Vol. 2 Nano Science and Technology Institute, 2014. p. 311-314.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Knights-Mitchell, SS & Romanowski, M 2014, Modification of commercial liposomal drug carrier by plasmon resonant coating. in Technical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014. vol. 2, Nano Science and Technology Institute, pp. 311-314, Nanotechnology 2014: MEMS, Fluidics, Bio Systems, Medical, Computational and Photonics - 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014, Washington, DC, United States, 6/15/14.
Knights-Mitchell SS, Romanowski M. Modification of commercial liposomal drug carrier by plasmon resonant coating. In Technical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014. Vol. 2. Nano Science and Technology Institute. 2014. p. 311-314
Knights-Mitchell, S. S. ; Romanowski, Marek. / Modification of commercial liposomal drug carrier by plasmon resonant coating. Technical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014. Vol. 2 Nano Science and Technology Institute, 2014. pp. 311-314
@inproceedings{b086e7abf4544c839b81895897278def,
title = "Modification of commercial liposomal drug carrier by plasmon resonant coating",
abstract = "Multiple liposomal drugs have been successfully marketed as pharmaceuticals within the past two decades. Some of these clinically approved drugs, Doxil{\circledR} in particular, have been shown to selectively localize within tumors due to the enhanced permeability and retention effect. However, a limitation exists with the inability to control content release once the drug gets to the desired location. Here we investigated the ability to apply a plasmon resonant coating to commercially available Doxil with the intention of spatially and temporally controlling doxorubicin release. While Doxil was successfully gold coated with a maximum plasmon resonant peak at 631 nm, the release at elevated temperature and on exposure to light was less than 10{\%}. This result is similar to that observed for uncoated Doxil. Decreasing the pH had the same effect on both uncoated and plasmon resonant sample where a 10{\%} increase in release was observed after samples were exposed to elevated temperature. Development of a highly efficient mechanism of light-activated drug release from Doxil will require a temperature-sensitive lipid composition.",
keywords = "Controlled release, Doxil, Doxorubicin, Liposomes, Plasmon resonance",
author = "Knights-Mitchell, {S. S.} and Marek Romanowski",
year = "2014",
language = "English (US)",
isbn = "9781482258271",
volume = "2",
pages = "311--314",
booktitle = "Technical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014",
publisher = "Nano Science and Technology Institute",

}

TY - GEN

T1 - Modification of commercial liposomal drug carrier by plasmon resonant coating

AU - Knights-Mitchell, S. S.

AU - Romanowski, Marek

PY - 2014

Y1 - 2014

N2 - Multiple liposomal drugs have been successfully marketed as pharmaceuticals within the past two decades. Some of these clinically approved drugs, Doxil® in particular, have been shown to selectively localize within tumors due to the enhanced permeability and retention effect. However, a limitation exists with the inability to control content release once the drug gets to the desired location. Here we investigated the ability to apply a plasmon resonant coating to commercially available Doxil with the intention of spatially and temporally controlling doxorubicin release. While Doxil was successfully gold coated with a maximum plasmon resonant peak at 631 nm, the release at elevated temperature and on exposure to light was less than 10%. This result is similar to that observed for uncoated Doxil. Decreasing the pH had the same effect on both uncoated and plasmon resonant sample where a 10% increase in release was observed after samples were exposed to elevated temperature. Development of a highly efficient mechanism of light-activated drug release from Doxil will require a temperature-sensitive lipid composition.

AB - Multiple liposomal drugs have been successfully marketed as pharmaceuticals within the past two decades. Some of these clinically approved drugs, Doxil® in particular, have been shown to selectively localize within tumors due to the enhanced permeability and retention effect. However, a limitation exists with the inability to control content release once the drug gets to the desired location. Here we investigated the ability to apply a plasmon resonant coating to commercially available Doxil with the intention of spatially and temporally controlling doxorubicin release. While Doxil was successfully gold coated with a maximum plasmon resonant peak at 631 nm, the release at elevated temperature and on exposure to light was less than 10%. This result is similar to that observed for uncoated Doxil. Decreasing the pH had the same effect on both uncoated and plasmon resonant sample where a 10% increase in release was observed after samples were exposed to elevated temperature. Development of a highly efficient mechanism of light-activated drug release from Doxil will require a temperature-sensitive lipid composition.

KW - Controlled release

KW - Doxil

KW - Doxorubicin

KW - Liposomes

KW - Plasmon resonance

UR - http://www.scopus.com/inward/record.url?scp=84907390442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907390442&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:84907390442

SN - 9781482258271

VL - 2

SP - 311

EP - 314

BT - Technical Proceedings of the 2014 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2014

PB - Nano Science and Technology Institute

ER -